A phase I, sequential cohort, dose escalation trial to determine the safety, tolerability, and maximum tolerated dose of daily oral administration of AV-412 in patients with refractory or relapsed solid tumor malignancies

Trial Profile

A phase I, sequential cohort, dose escalation trial to determine the safety, tolerability, and maximum tolerated dose of daily oral administration of AV-412 in patients with refractory or relapsed solid tumor malignancies

Discontinued
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2011

At a glance

  • Drugs AV 412 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Jul 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 23 Jan 2009 Planned end date changed from Mar 2009 to Mar 2010 as reported by ClinicalTrials.gov.
    • 10 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top